<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1609303A-B817-4C20-9FE6-3BB523B84410"><gtr:id>1609303A-B817-4C20-9FE6-3BB523B84410</gtr:id><gtr:name>Fondazione IRCCS Istituto Nazionale dei Tumori</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/25389450-3558-429C-90CF-8802243577D3"><gtr:id>25389450-3558-429C-90CF-8802243577D3</gtr:id><gtr:name>National Cancer Institute (CRO)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E37A07A-3992-42A3-AAB1-4AE3A98DC69A"><gtr:id>5E37A07A-3992-42A3-AAB1-4AE3A98DC69A</gtr:id><gtr:name>University of Calabria</gtr:name><gtr:address><gtr:line1>University of Calabria</gtr:line1><gtr:line2>C-da Arcavacata</gtr:line2><gtr:line4>87036 Rende</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8F857011-7088-454D-847A-653BCA87E6E6"><gtr:id>8F857011-7088-454D-847A-653BCA87E6E6</gtr:id><gtr:name>Fondo Edo Tempia Biella</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4C02B63A-6450-44EE-B38C-5D2C0C38D1E8"><gtr:id>4C02B63A-6450-44EE-B38C-5D2C0C38D1E8</gtr:id><gtr:name>University of Rome II (Tor Vergata)</gtr:name><gtr:address><gtr:line1>via Columbia, 2</gtr:line1><gtr:line4>Roma</gtr:line4><gtr:line5>I-00133</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9EED95BB-25DC-4032-8E45-C3EA7277E78A"><gtr:id>9EED95BB-25DC-4032-8E45-C3EA7277E78A</gtr:id><gtr:name>University of Milan</gtr:name><gtr:address><gtr:line1>Via Festa del Perdono 7</gtr:line1><gtr:postCode>20122</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95524E5B-E175-4691-AADA-C3E30E53A1F7"><gtr:id>95524E5B-E175-4691-AADA-C3E30E53A1F7</gtr:id><gtr:name>University of Cologne</gtr:name><gtr:address><gtr:line1>Fachbereich Wirtschaft</gtr:line1><gtr:line2>Claudrusstra?e 1</gtr:line2><gtr:line4>D-50678 Cologne</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Blizard Institute of Cell and Molecular</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1609303A-B817-4C20-9FE6-3BB523B84410"><gtr:id>1609303A-B817-4C20-9FE6-3BB523B84410</gtr:id><gtr:name>Fondazione IRCCS Istituto Nazionale dei Tumori</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/25389450-3558-429C-90CF-8802243577D3"><gtr:id>25389450-3558-429C-90CF-8802243577D3</gtr:id><gtr:name>National Cancer Institute (CRO)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E37A07A-3992-42A3-AAB1-4AE3A98DC69A"><gtr:id>5E37A07A-3992-42A3-AAB1-4AE3A98DC69A</gtr:id><gtr:name>University of Calabria</gtr:name><gtr:address><gtr:line1>University of Calabria</gtr:line1><gtr:line2>C-da Arcavacata</gtr:line2><gtr:line4>87036 Rende</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8F857011-7088-454D-847A-653BCA87E6E6"><gtr:id>8F857011-7088-454D-847A-653BCA87E6E6</gtr:id><gtr:name>Fondo Edo Tempia Biella</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4C02B63A-6450-44EE-B38C-5D2C0C38D1E8"><gtr:id>4C02B63A-6450-44EE-B38C-5D2C0C38D1E8</gtr:id><gtr:name>University of Rome II (Tor Vergata)</gtr:name><gtr:address><gtr:line1>via Columbia, 2</gtr:line1><gtr:line4>Roma</gtr:line4><gtr:line5>I-00133</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED"><gtr:id>6BE14EEB-8C76-4661-A42D-5BBE8B8AC5ED</gtr:id><gtr:name>Technical University Dresden</gtr:name><gtr:address><gtr:line1>TU Dresden</gtr:line1><gtr:postCode>D-01062</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9EED95BB-25DC-4032-8E45-C3EA7277E78A"><gtr:id>9EED95BB-25DC-4032-8E45-C3EA7277E78A</gtr:id><gtr:name>University of Milan</gtr:name><gtr:address><gtr:line1>Via Festa del Perdono 7</gtr:line1><gtr:postCode>20122</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95524E5B-E175-4691-AADA-C3E30E53A1F7"><gtr:id>95524E5B-E175-4691-AADA-C3E30E53A1F7</gtr:id><gtr:name>University of Cologne</gtr:name><gtr:address><gtr:line1>Fachbereich Wirtschaft</gtr:line1><gtr:line2>Claudrusstra?e 1</gtr:line2><gtr:line4>D-50678 Cologne</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D3295C97-E8FF-4C36-9D58-7F85DF5B5ED0"><gtr:id>D3295C97-E8FF-4C36-9D58-7F85DF5B5ED0</gtr:id><gtr:firstName>Rubeta</gtr:firstName><gtr:otherNames>Nishat</gtr:otherNames><gtr:surname>Matin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600450"><gtr:id>16FD546D-59F5-4FB8-9056-7BE58FB84FBB</gtr:id><gtr:title>p53 family members and apoptosis in malignant melanoma: a role in chemoresistance?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0600450</gtr:grantReference><gtr:abstractText>We are investigating why melanoma, an aggressive form of skin cancer, is so resistant to chemotherapy, and how new treatments might be able to overcome this resistance. In the UK 8,100 new cases of melanoma are diagnosed annually with the incidence predicted to treble in the next 30 years. Melanoma arises from the pigment-producing cells (melanocytes) in skin and both its development and resistance to standard cancer treatments is thought in part due to the resistance of cells to apoptosis - a form of cell death. Essential to apoptosis is the p53 gene and loss of p53 activity is frequently implicated in other cancers. p53 also plays a crucial role in protecting against skin cancer induced by ultraviolet radiation (UVR). The aim of this project is to study the p53 family of proteins and their interacting roles in UVR-induced cell death in melanocytes and melanoma. Melanoma represents a major burden on public health and healthcare resources. This project will determine the mechanism of p53 inactivation in melanoma. Information obtained will further our understanding of changes in melanocytes as they undergo malignant progression and provide new ways to develop treatments that are effective.</gtr:abstractText><gtr:technicalSummary>Malignant melanoma is the most aggressive form of skin cancer. Its incidence has increased more rapidly than that of any other cancer in the last 30 years. Advanced disease has poor prognosis and is notoriously resistant to all current therapeutic modalities. Unlike many other malignancies, p53 mutations are infrequent in melanoma implicating aberrant upstream or downstream components of the p53 signalling pathway. In the proposed study the hypothesis that the p53 family members are determinants of chemosensitivity and chemoresistance in melanoma will be tested. 

The specific aims of the study are to assess the integrity of the p53 signalling pathway including downstream target genes and co-activators of p53 family members in normal melanocytes and melanoma cell lines and to relate this to cellular response to genotoxins including ultraviolet radiation (UV) and cytotoxic drugs. Experiments will first establish the existence of post-translational modifications (specifically phosphorylation and acetylation) of p53 and p73 following genotoxic stress in melanocytes and melanoma cell lines. Using p53 target gene micro-arrays the p53 transcriptosome will be analysed following genotoxic stress in primary melanocytes and melanoma cell lines of varying sensitivity to DNA damage. Expression patterns of pro-apoptotic co-activators will be monitored (in collaboration) to seek correlations between patterns of target gene expression, co-activator expression and cellular response to DNA damage.

Expression patterns of each p53 family member and their splice variants will be established in control cultures and in tissue samples obtained prospectively. The role of individual p53 family members in UV-induced apoptosis will be examined by FACS analysis by exposing p53 wild-type and p53 null melanoma cell lines to different doses of UVB, UVA and DNA-damaging agents. Experiments to upregulate (by transfection or lentiviral infection) and/or deplete p63, p73 and their splice variants (by siRNAi and micro-siRNAi) will determine the chemosensitivity of melanoma cells to relevant genotoxic stimuli. Melanoma cell lines and a spectrum of melanocytic lesions from the patient cohort will also be screened for p53 polymorphic variants to investigate their synergistic roles with p53 family members in UV-induced apoptotic cell death and correlation with clinical outcomes respectively.
 
The proposed work combines both functional/mechanistic studies and the molecular pathological analysis of tumour samples to assess the clinical significance of in vitro results. Determining the molecular basis of the intrinsic resistance of melanocytes to apoptosis during malignant progression may provide insight into potential therapeutic targets for overcoming their acquired chemoresistance.</gtr:technicalSummary><gtr:fund><gtr:end>2009-12-03</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-12-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>188520</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Toxicology Unit</gtr:department><gtr:description>p63 expression</gtr:description><gtr:id>DCED2E06-F4E8-4AF6-AF75-7C186C05784C</gtr:id><gtr:impact>Publication reported and one pending plus funding</gtr:impact><gtr:outcomeId>azswPtf2EAG-2</gtr:outcomeId><gtr:partnerContribution>Publication pending and funding approvalTools reagents and antibodies for detecting p63 expression in melanoma cell linesCD133 expression in p63 positive melanoma cells</gtr:partnerContribution><gtr:piContribution>Tools reagents and antibodies for detecting p63 expression in melanoma cell lines</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Rome Tor Vergata</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>p63/p53 signalling in melanoma</gtr:description><gtr:id>5641E042-83A2-44F0-AEFC-9B973CEFFE9D</gtr:id><gtr:impact>Publications listed and other outputs pending</gtr:impact><gtr:outcomeId>GHJ9dBr2WJt-2</gtr:outcomeId><gtr:partnerContribution>Signalling pathwaysSignallng pathwaysp53 short isoforms and p53 Arg72Pro SNP in melanomaBak &amp;amp; p53 mitochondrial relocation in melanoma</gtr:partnerContribution><gtr:piContribution>Provision of melanoma cell lines, reagents and sharing of data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fondo Edo Tempia Biella</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Characterisation of melanoma</gtr:description><gtr:id>E805A5BE-6073-4CE6-89F0-5018282BC21F</gtr:id><gtr:impact>Multi-disciplinary - resulted in characterisation of mutation status of melanoma lines which has led to further funding and included in publication (pending)</gtr:impact><gtr:outcomeId>o8P9kvtP1sp-2</gtr:outcomeId><gtr:partnerContribution>Established melanoma cell lines with characterized status of BRAF/NRAS mutationsGenome wide microarray analysis and microRNA profiling of melanoma cell lines silenced for p63Dissecting the role of YAP in melanomaApoptosis and DNA repair in melanoma</gtr:partnerContribution><gtr:piContribution>We have provided the melanoma cell lines in which to determine the mutation status</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Oncology and Molecular Medicine</gtr:department><gtr:description>Serum Epigenetic Biomarkers for Metastatic Melanoma</gtr:description><gtr:id>2222FA55-5E16-49AB-90FC-00A3A5FABFB5</gtr:id><gtr:impact>Pending</gtr:impact><gtr:outcomeId>kyQyhKMrzdy-1</gtr:outcomeId><gtr:partnerContribution>Collaborative study investigating biomarkers in melanoma relapse - lab research and statistical analyses undertaken at this site.</gtr:partnerContribution><gtr:piContribution>Collaborative study investigating biomarkers in melanoma relapse - retrospective and prospective collection of samples.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Targeting p63</gtr:description><gtr:id>B573FE3A-1D9C-4E90-8B6F-0118AB6B0C3A</gtr:id><gtr:impact>Publication listed</gtr:impact><gtr:outcomeId>DQyL9tDzwDH-4</gtr:outcomeId><gtr:partnerContribution>Publication listedThe role of TINT in melanoma metastasisEpigenetic regulation of novel target genes in melanomaEpigenetic regulation of novel target genes in melanoma</gtr:partnerContribution><gtr:piContribution>Cell lines, reagents and data sharing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Rome Tor Vergata</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>p63 expression</gtr:description><gtr:id>6C704A7C-BB95-496F-9103-B693AE2C8403</gtr:id><gtr:impact>Publication reported and one pending plus funding</gtr:impact><gtr:outcomeId>azswPtf2EAG-1</gtr:outcomeId><gtr:partnerContribution>Publication pending and funding approvalTools reagents and antibodies for detecting p63 expression in melanoma cell linesCD133 expression in p63 positive melanoma cells</gtr:partnerContribution><gtr:piContribution>Tools reagents and antibodies for detecting p63 expression in melanoma cell lines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cologne</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>Targeting p63</gtr:description><gtr:id>5005C564-3929-4DFE-B3AB-910125DFF4C7</gtr:id><gtr:impact>Publication listed</gtr:impact><gtr:outcomeId>DQyL9tDzwDH-1</gtr:outcomeId><gtr:partnerContribution>Publication listedThe role of TINT in melanoma metastasisEpigenetic regulation of novel target genes in melanomaEpigenetic regulation of novel target genes in melanoma</gtr:partnerContribution><gtr:piContribution>Cell lines, reagents and data sharing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Cancer Institute (CRO)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Characterisation of melanoma</gtr:description><gtr:id>CF8832E0-EEE0-4EB1-8F25-BF15929D68B4</gtr:id><gtr:impact>Multi-disciplinary - resulted in characterisation of mutation status of melanoma lines which has led to further funding and included in publication (pending)</gtr:impact><gtr:outcomeId>o8P9kvtP1sp-3</gtr:outcomeId><gtr:partnerContribution>Established melanoma cell lines with characterized status of BRAF/NRAS mutationsGenome wide microarray analysis and microRNA profiling of melanoma cell lines silenced for p63Dissecting the role of YAP in melanomaApoptosis and DNA repair in melanoma</gtr:partnerContribution><gtr:piContribution>We have provided the melanoma cell lines in which to determine the mutation status</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Establishing a correlation between ?Np63 and IGFBP7 in melanoma cells</gtr:description><gtr:id>A6EC290C-3608-4EEC-AF0A-D24FE333BE06</gtr:id><gtr:impact>Pending</gtr:impact><gtr:outcomeId>cqNWNuhRRoJ-1</gtr:outcomeId><gtr:piContribution>Melanoma cell lines provision and data sharing</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and The London School of Medicine and Dentistry</gtr:department><gtr:description>Targeting p63</gtr:description><gtr:id>6016C1DF-445E-480A-B42B-A3AE5D83EA26</gtr:id><gtr:impact>Publication listed</gtr:impact><gtr:outcomeId>DQyL9tDzwDH-2</gtr:outcomeId><gtr:partnerContribution>Publication listedThe role of TINT in melanoma metastasisEpigenetic regulation of novel target genes in melanomaEpigenetic regulation of novel target genes in melanoma</gtr:partnerContribution><gtr:piContribution>Cell lines, reagents and data sharing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Milan</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>p63/p53 signalling in melanoma</gtr:description><gtr:id>9A472253-C53F-46B5-8783-942598B46ED9</gtr:id><gtr:impact>Publications listed and other outputs pending</gtr:impact><gtr:outcomeId>GHJ9dBr2WJt-1</gtr:outcomeId><gtr:partnerContribution>Signalling pathwaysSignallng pathwaysp53 short isoforms and p53 Arg72Pro SNP in melanomaBak &amp;amp; p53 mitochondrial relocation in melanoma</gtr:partnerContribution><gtr:piContribution>Provision of melanoma cell lines, reagents and sharing of data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ASPP Proteins</gtr:description><gtr:id>C5D24912-87F0-4C12-B7D3-325C9A197D39</gtr:id><gtr:impact>Publication listed</gtr:impact><gtr:outcomeId>goBVmU4fWFb-1</gtr:outcomeId><gtr:partnerContribution>Involvement of the ASPP proteins in Autophagy</gtr:partnerContribution><gtr:piContribution>Involvement of the ASPP proteins in Autophagy</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>p63/p53 signalling in melanoma</gtr:description><gtr:id>DDB1C3A5-0D09-4424-83C0-E02B73569039</gtr:id><gtr:impact>Publications listed and other outputs pending</gtr:impact><gtr:outcomeId>GHJ9dBr2WJt-4</gtr:outcomeId><gtr:partnerContribution>Signalling pathwaysSignallng pathwaysp53 short isoforms and p53 Arg72Pro SNP in melanomaBak &amp;amp; p53 mitochondrial relocation in melanoma</gtr:partnerContribution><gtr:piContribution>Provision of melanoma cell lines, reagents and sharing of data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Technical University of Dresden</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>p63 expression</gtr:description><gtr:id>AC8D9750-46F0-490C-B969-B41AB2FEDFEB</gtr:id><gtr:impact>Publication reported and one pending plus funding</gtr:impact><gtr:outcomeId>azswPtf2EAG-3</gtr:outcomeId><gtr:partnerContribution>Publication pending and funding approvalTools reagents and antibodies for detecting p63 expression in melanoma cell linesCD133 expression in p63 positive melanoma cells</gtr:partnerContribution><gtr:piContribution>Tools reagents and antibodies for detecting p63 expression in melanoma cell lines</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fondazione IRCCS Istituto Nazionale dei Tumori</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>World melanoma study</gtr:description><gtr:id>CCF3E12A-F0CD-4FC4-9773-92A2E2031D93</gtr:id><gtr:impact>Pending</gtr:impact><gtr:outcomeId>eCibcj4QacG-1</gtr:outcomeId><gtr:piContribution>World melanoma study to compare multiple versus sporadic melanoma</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fondazione IRCCS Istituto Nazionale dei Tumori</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Characterisation of melanoma</gtr:description><gtr:id>857BD905-9CEA-43CE-A134-74B666F65602</gtr:id><gtr:impact>Multi-disciplinary - resulted in characterisation of mutation status of melanoma lines which has led to further funding and included in publication (pending)</gtr:impact><gtr:outcomeId>o8P9kvtP1sp-1</gtr:outcomeId><gtr:partnerContribution>Established melanoma cell lines with characterized status of BRAF/NRAS mutationsGenome wide microarray analysis and microRNA profiling of melanoma cell lines silenced for p63Dissecting the role of YAP in melanomaApoptosis and DNA repair in melanoma</gtr:partnerContribution><gtr:piContribution>We have provided the melanoma cell lines in which to determine the mutation status</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Calabria</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>Characterisation of melanoma</gtr:description><gtr:id>B5650053-C535-4773-A012-D2356823E1E4</gtr:id><gtr:impact>Multi-disciplinary - resulted in characterisation of mutation status of melanoma lines which has led to further funding and included in publication (pending)</gtr:impact><gtr:outcomeId>o8P9kvtP1sp-4</gtr:outcomeId><gtr:partnerContribution>Established melanoma cell lines with characterized status of BRAF/NRAS mutationsGenome wide microarray analysis and microRNA profiling of melanoma cell lines silenced for p63Dissecting the role of YAP in melanomaApoptosis and DNA repair in melanoma</gtr:partnerContribution><gtr:piContribution>We have provided the melanoma cell lines in which to determine the mutation status</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>p63/p53 signalling in melanoma</gtr:description><gtr:id>4AFDD4FF-2EB5-437E-9C6C-9561F3D450AA</gtr:id><gtr:impact>Publications listed and other outputs pending</gtr:impact><gtr:outcomeId>GHJ9dBr2WJt-3</gtr:outcomeId><gtr:partnerContribution>Signalling pathwaysSignallng pathwaysp53 short isoforms and p53 Arg72Pro SNP in melanomaBak &amp;amp; p53 mitochondrial relocation in melanoma</gtr:partnerContribution><gtr:piContribution>Provision of melanoma cell lines, reagents and sharing of data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Dundee Cancer Centre</gtr:department><gtr:description>Targeting p63</gtr:description><gtr:id>BE54BED7-D2DA-4098-A1F8-9A6ECC3D45C6</gtr:id><gtr:impact>Publication listed</gtr:impact><gtr:outcomeId>DQyL9tDzwDH-3</gtr:outcomeId><gtr:partnerContribution>Publication listedThe role of TINT in melanoma metastasisEpigenetic regulation of novel target genes in melanomaEpigenetic regulation of novel target genes in melanoma</gtr:partnerContribution><gtr:piContribution>Cell lines, reagents and data sharing</gtr:piContribution><gtr:sector>Multiple</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>162862</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Barts and the London Charitable Foundation/CRUK project grant</gtr:description><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>38FE70C4-10BF-4311-8C75-D807A6DE542A</gtr:id><gtr:outcomeId>sN1RfYJZyNo1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>138800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Barts and the London Charity Strategic Research Grant</gtr:description><gtr:end>2013-11-02</gtr:end><gtr:fundingOrg>Barts Charity</gtr:fundingOrg><gtr:fundingRef>Title: Exploring novel molecular targets in non-BRAF mutated metastatic melanoma.</gtr:fundingRef><gtr:id>150B6699-8EDE-401A-890C-94A1F359A81D</gtr:id><gtr:outcomeId>DhcUWCSrLDX0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Barts and the London Charity Research Fund</gtr:description><gtr:fundingOrg>Barts Charity</gtr:fundingOrg><gtr:id>3FE9245E-19CF-4C34-9EE0-58EBF08E774A</gtr:id><gtr:outcomeId>A1MVhZXyRNJ0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship 2</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>75FD16D6-60A5-41B5-96BC-62FB2E2EB07B</gtr:id><gtr:outcomeId>Pud6uedr75G0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>99858</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Barts and the London Charitable Foundation/CRUK project grant</gtr:description><gtr:fundingOrg>Barts Charity</gtr:fundingOrg><gtr:id>50461366-3417-483F-831C-4F88E58E8BB8</gtr:id><gtr:outcomeId>sN1RfYJZyNo0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant Award</gtr:description><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>E7943E55-F96B-440E-AC43-6463CBDE40B7</gtr:id><gtr:outcomeId>rcsYGmMGqic0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Melanoma Focus Patient Impact Project</gtr:description><gtr:fundingOrg>Melanoma Focus</gtr:fundingOrg><gtr:id>E6121A82-1C1D-4BB9-AE14-CAA146E577DE</gtr:id><gtr:outcomeId>KQjPEgbU1Dk</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>81000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BSF PhD Studentship</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>British Skin Foundation</gtr:fundingOrg><gtr:fundingRef>Title: Dissecting the role of iASPP, a novel crucial regulator of epidermal homeostasis, in keratinocyte skin carcinogenesis.</gtr:fundingRef><gtr:id>E1521EFC-11A6-4F92-83CB-F7AE8C2C7B91</gtr:id><gtr:outcomeId>DMMapb1fUYk</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>380467B3-826E-4F81-89D9-23FFB13DADEA</gtr:id><gtr:outcomeId>FGUDn3Daoyf0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Melanoma tissue samples and cell lines of varying stage of disease.</gtr:description><gtr:id>7DE42C08-7DE5-4809-802A-6F420E968EE2</gtr:id><gtr:impact>Investigation of aberrations in other molecular pathways e.g. Wnt signalling pathway</gtr:impact><gtr:outcomeId>CCPv7zgWcRs</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Tissue Bank</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>55A7FFAA-33E5-4B60-B133-25026FF373B4</gtr:id><gtr:title>Melanoma in organ transplant recipients: clinicopathological features and outcome in 100 cases.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45947e4f0ce6e9053edf1a9e1192e79a"><gtr:id>45947e4f0ce6e9053edf1a9e1192e79a</gtr:id><gtr:otherNames>Matin RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>q65zp3Y2X33</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EDCBE99-2DD7-45A5-9EF0-71653A351292</gtr:id><gtr:title>Cutaneous mucinous carcinoma arising in extramammary Paget disease of the perineum.</gtr:title><gtr:parentPublicationTitle>The American Journal of dermatopathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45947e4f0ce6e9053edf1a9e1192e79a"><gtr:id>45947e4f0ce6e9053edf1a9e1192e79a</gtr:id><gtr:otherNames>Matin RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0193-1091</gtr:issn><gtr:outcomeId>purNM6TS8fN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BDA63AEE-5590-4A91-8386-987C9EE72E1D</gtr:id><gtr:title>iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia.</gtr:title><gtr:parentPublicationTitle>The EMBO journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4f030e9f9e8916f34d372eb7ab4769ac"><gtr:id>4f030e9f9e8916f34d372eb7ab4769ac</gtr:id><gtr:otherNames>Chikh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0261-4189</gtr:issn><gtr:outcomeId>aK4QfwtUKau</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B1F562A-E6D2-497C-BF79-CF482BC3DF6C</gtr:id><gtr:title>Metastatic cutaneous squamous cell carcinoma shows frequent deletion in the protein tyrosine phosphatase receptor Type D gene.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42fe0f9323b9f04122ec89eb6572451a"><gtr:id>42fe0f9323b9f04122ec89eb6572451a</gtr:id><gtr:otherNames>Lambert SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>ocbChG6To4e</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98DBA8C2-E58F-4C10-8AEE-CE08F287F14F</gtr:id><gtr:title>KIT and BRAF mutational status in a patient with a synchronous lentigo maligna melanoma and a gastrointestinal stromal tumor.</gtr:title><gtr:parentPublicationTitle>American journal of clinical dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45947e4f0ce6e9053edf1a9e1192e79a"><gtr:id>45947e4f0ce6e9053edf1a9e1192e79a</gtr:id><gtr:otherNames>Matin RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1175-0561</gtr:issn><gtr:outcomeId>pm_16538_28_22175303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A9070BF8-F6B3-4FE0-8562-6B65C1BC8C84</gtr:id><gtr:title>Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/50eb39f9164f9bc8e8703b7fe9d6644d"><gtr:id>50eb39f9164f9bc8e8703b7fe9d6644d</gtr:id><gtr:otherNames>Lo Nigro C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>doi_16538_d_2012_493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5DF17F1-AA6F-43E1-9162-A4D730CF17BB</gtr:id><gtr:title>NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f88cc0b3857e4454158c5b9ddf455220"><gtr:id>f88cc0b3857e4454158c5b9ddf455220</gtr:id><gtr:otherNames>Wang H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_16538_28_22454080</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06BC0D9A-4FB1-4196-AC8C-E9CF44CAEF1E</gtr:id><gtr:title>Synchronous melanoma and renal carcinoma: a clinicopathological study of five cases.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45947e4f0ce6e9053edf1a9e1192e79a"><gtr:id>45947e4f0ce6e9053edf1a9e1192e79a</gtr:id><gtr:otherNames>Matin RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>pm_16538_28_22681124</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A90F6F1-9638-42FD-B128-1F0340830D1A</gtr:id><gtr:title>p63 is an alternative p53 repressor in melanoma that confers chemoresistance and a poor prognosis.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/45947e4f0ce6e9053edf1a9e1192e79a"><gtr:id>45947e4f0ce6e9053edf1a9e1192e79a</gtr:id><gtr:otherNames>Matin RN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>doi_16538_m_20121439</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600450</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>006DC612-6329-4D37-A540-5FB2CA634720</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.5  Radiotherapy</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>